Research analysts covering PURPLE BIOTECH.
Recent press releases and 8-K filings for PPBT.
Purple Biotech Highlights Pipeline Progress and Financial Position in January 2026 Presentation
PPBT
New Projects/Investments
Guidance Update
- Purple Biotech reported $10.5 million in cash as of September 30, 2025, with a cash runway extending into H1 2027.
- The company's lead program, IM1240, a tri-specific antibody from the CAPTN-3 platform, is on track for Phase 1 initiation in H2 2026, supported by successful non-GLP toxicology studies and a clear roadmap from the FDA.
- CM24 (pancreatic cancer) and NT219 (head and neck cancer), two clinical-stage assets, are available for partnership; CM24 demonstrated a 19% reduction in risk of death and 25% reduction in risk of progression or death in metastatic pancreatic cancer patients.
- Key milestones anticipated in 2026 include the completion of IM1240 GLP Tox, IND submission, and Phase 1 initiation, alongside interim data for NT219 and potential partnership for CM24.
Jan 13, 2026, 12:18 AM
Purple Biotech Reports Positive Preclinical Data for CAPTN-3 Tri-Specific Antibody Platform
PPBT
Product Launch
New Projects/Investments
- Purple Biotech Ltd. reported positive new preclinical data for its CAPTN-3 tri-specific antibody platform at the ESMO Immuno-Oncology Congress 2025 on December 11, 2025.
- The data demonstrated multi-arm anti-tumor activity across two candidates: IM1240 and IM1305.
- IM1240 exhibited significant anti-tumor activity in PD1-resistant ex-vivo models, with its efficacy dependent on both CD3 and NKG2A arms.
- IM1305, a new TROP2-targeting candidate, showed potent tumor cell killing across various tumor types and sustained tumor regression in humanized triple-negative breast cancer mouse models.
- The company is advancing CAPTN-3 toward IND-enabling studies and expects key milestones in 2026, highlighting the platform's versatility and scalability.
Dec 11, 2025, 12:01 PM
Purple Biotech Ltd. Provides Q3 2025 Corporate Presentation Update
PPBT
New Projects/Investments
Guidance Update
- Purple Biotech Ltd. reported a cash balance of $10.5 million as of September 30, 2025, which is expected to provide a financial runway into the first half of 2027.
- The company's CM24 drug candidate, an aCEACAM1 antibody, demonstrated positive randomized Phase 2a results in metastatic pancreatic ductal adenocarcinoma (PDAC), showing a 19% reduction in the risk of death and a 25% reduction in the risk of progression or death.
- NT219, an IRS1/2 degrader and STAT3 blocker, has shown safety and anti-tumor activity in Phase 1 and initiated a Phase 2 study in June 2025 for recurrent/metastatic head and neck cancer (R/M HNSCC).
- The CAPTN-3 tri-specific antibody platform, including IM1240, has IND submission planned for mid-2026 and first-in-human (FIH) clinical trials in the second half of 2026.
Nov 19, 2025, 10:07 PM
Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update
PPBT
Earnings
New Projects/Investments
- Purple Biotech reported a net loss of $1.3 million, or $0.29 per basic and diluted ADS, for the three months ended September 30, 2025.
- The company's operating loss for the third quarter of 2025 was $1.4 million, representing a 35.8% decrease compared to the same period in 2024.
- As of September 30, 2025, Purple Biotech had $10.5 million in cash and cash equivalents and short-term deposits, with an anticipated cash runway into the first half of 2027.
- The company initiated development of IM1305, a second CAPTN-3 tri-specific antibody targeting TROP2, and achieved a manufacturing milestone for IM1240, with IND submission and study initiation for IM1240 planned for 2026.
Nov 14, 2025, 1:17 PM
Purple Biotech achieves manufacturing milestone for IM1240
PPBT
New Projects/Investments
- Purple Biotech Ltd. announced on October 29, 2025, the achievement of a manufacturing milestone for IM1240, a tri-specific antibody from its CAPTN-3 platform, by establishing a commercially viable yield and validating the platform's scalability.
- IM1240, the first CAPTN-3 tri-specific antibody, is advancing toward first-in-human clinical trials, with an Investigational New Drug (IND) submission planned for 2026.
- The company developed a high-efficiency manufacturing and purification process for tri-specific antibodies, designed to deliver a differentiated T cell engager with a capped, cleavable polypeptide to help prevent off-tumor immune activation.
Oct 29, 2025, 11:33 AM
Purple Biotech receives Nasdaq minimum bid price notification
PPBT
Delisting/Listing Issues
- Purple Biotech Ltd. (PPBT) received a Nasdaq notification on October 16, 2025, for non-compliance with the $1.00 minimum bid price rule, as its American Depositary Shares (ADSs) traded below this threshold for 30 consecutive days.
- The company has 180 calendar days, until April 14, 2026, to regain compliance by achieving a closing bid price of $1.00 or more for ten consecutive business days.
- This notification has no immediate effect on the company's Nasdaq listing or the trading of its ADSs.
- Purple Biotech intends to monitor its ADS bid price and may consider options to cure the deficiency, including potentially changing the ratio between its ADSs and ordinary shares.
Oct 20, 2025, 8:01 PM
Purple Biotech Enters New At The Market Offering Agreement
PPBT
- Purple Biotech Ltd. entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC on September 19, 2025, to offer and sell American Depositary Shares (ADSs) with an aggregate offering price of up to $2,300,000.
- Each ADS under the new agreement represents 200 ordinary shares, and H.C. Wainwright & Co., LLC will receive a 3.0% placement fee on the gross sales price.
- Effective September 18, 2025, the company terminated its Open Market Sale Agreement with Jefferies LLC.
- Under the terminated Jefferies ATM Program, Purple Biotech sold 983,317 ADSs for aggregate gross proceeds of $7,729,691, at an average price of $7.86 per ADS.
Sep 19, 2025, 9:28 PM
Purple Biotech Presents September 2025 Corporate Update
PPBT
Product Launch
New Projects/Investments
Guidance Update
- Purple Biotech reported a cash balance of $10.5 million as of September 10, 2025, providing a cash runway into the first half of 2027.
- The company is progressing two first-in-class drugs in Phase 2: CM24, an aCEACAM1 antibody with positive randomized Phase 2a results for pancreatic cancer, and NT219, an IRS1/2 degrader and STAT3 blocker, which initiated a Phase 2 study in June 2025 for recurrent/metastatic Head & Neck Cancer.
- Development continues for CAPTN-3, a next-generation tri-specific antibody platform, with first-in-human trials anticipated in 2026.
Sep 15, 2025, 11:20 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more